Indeed, overexpression of PIM1 in ALK-positive ALCL cell lines decreased sensitivity to brigatinib and ceritinib, consistent with results published previously demonstrating robust synergy between a small-molecule pan-PIM inhibitor and crizotinib in ALCL cell lines40. Here, ALK is linked to anaplastic large cell lymphoma.